Flamogrel (clopidogrel) coated tablets 75 mg. №30


Manufacturer: India



Prevention of atherothrombosis in adults in patients who have suffered a myocardial infarction (treatment begins a few days later, but not later than 35 days after its occurrence), ischemic stroke (treatment begins 7 days later, but not later than 6 months after its occurrence) , or who have been diagnosed with peripheral artery disease (arterial damage and atherothrombosis of the lower extremities); in patients with acute coronary syndrome: with acute coronary syndrome without St segment elevation (unstable angina or myocardial infarction without q wave), including in patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid with acute myocardial infarction with St segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical treatment and who are indicated for thrombolytic therapy). Prevention of atherothrombotic and thromboembolic events in atrial fibrillation Clopidogrel in combination with acetylsalicylic acid is indicated in adult patients with atrial fibrillation who have at least one risk factor for vascular events, in which there are contraindications to treatment with vitamin K antagonists and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke. For more information, see the section “Pharmacological properties”.